240
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab or Lenvatinib for Unresectable Hepatocellular Carcinoma: A Propensity Score Matched Study

, , , ORCID Icon, , & ORCID Icon show all
Pages 1195-1206 | Received 04 May 2023, Accepted 20 Jul 2023, Published online: 25 Jul 2023

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

For more information please visit our Permissions help page.